Abstract
Approximately 50% of humanity is infected with Helicobacter pylori. Normally, this is a life-long infection indicating that the host response to natural infection fails to yield protective immunity. Moreover, the chronic inflammatory response associated with this infection can contribute to tissue damage and the pathogenesis of gastroduodenal disease including atrophic gastritis, peptic ulcer and gastric cancer. These damaging immune responses are attributed to a subset of helper T cells, so-called Th1 cells, that enhance cell-mediated immunity and induce damage to the gastric epithelium. Thus, it is desirable to have effective vaccines that could prevent and cure infection or at least, modify the host response in a manner that prevents immune-mediated disease. Using animal models as a tool to understand the immunobiology of Helicobacter infections, several investigators have shown that effective vaccines can be developed. Thus, prophylactic and even therapeutic vaccines have been described in various animal models. The basis for the effectiveness of these vaccines seems to be found in their ability to alter the gastric immune response, perhaps away from a homogeneous Th1 response towards a mixed Th1 and Th2 response. Using these encouraging approaches, vaccines are being developed for use in humans for the treatment and prevention of H. pylori infection and the gastroduodenal diseases associated with this infection.
Current Pharmaceutical Design
Title: Preventive and Therapeutic Vaccines Against Helicobacter pylori: Current Status and Future Challenges
Volume: 6 Issue: 15
Author(s): Peter B. Ernst and Jacques Pappo
Affiliation:
Abstract: Approximately 50% of humanity is infected with Helicobacter pylori. Normally, this is a life-long infection indicating that the host response to natural infection fails to yield protective immunity. Moreover, the chronic inflammatory response associated with this infection can contribute to tissue damage and the pathogenesis of gastroduodenal disease including atrophic gastritis, peptic ulcer and gastric cancer. These damaging immune responses are attributed to a subset of helper T cells, so-called Th1 cells, that enhance cell-mediated immunity and induce damage to the gastric epithelium. Thus, it is desirable to have effective vaccines that could prevent and cure infection or at least, modify the host response in a manner that prevents immune-mediated disease. Using animal models as a tool to understand the immunobiology of Helicobacter infections, several investigators have shown that effective vaccines can be developed. Thus, prophylactic and even therapeutic vaccines have been described in various animal models. The basis for the effectiveness of these vaccines seems to be found in their ability to alter the gastric immune response, perhaps away from a homogeneous Th1 response towards a mixed Th1 and Th2 response. Using these encouraging approaches, vaccines are being developed for use in humans for the treatment and prevention of H. pylori infection and the gastroduodenal diseases associated with this infection.
Export Options
About this article
Cite this article as:
Ernst B. Peter and Pappo Jacques, Preventive and Therapeutic Vaccines Against Helicobacter pylori: Current Status and Future Challenges, Current Pharmaceutical Design 2000; 6 (15) . https://dx.doi.org/10.2174/1381612003399086
DOI https://dx.doi.org/10.2174/1381612003399086 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism
Current Diabetes Reviews Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets TGFb and its Smad Connection to Cancer
Current Genomics Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design Editorial (Hot Topic: Translational Medicine is Promoting Cross-talk of Interdiscipline)
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders
Current Pharmaceutical Design Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Diagnostic and Therapeutic Optical Imaging Techniques]
Current Medical Imaging Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention
Current Cancer Drug Targets Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review
Current Cancer Therapy Reviews Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells
Current Cancer Drug Targets